RET and thyroid cancer: Lenvatinib, a multi-kinase inhibitor to inhibit vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) alpha, KIT, and rearranged during transfection (RET), showed an effect in the progression-free survival and response rate in patients with radioiodine-refractory thyroid cancer [18].